2020 MCAS MEASURE: CHLAMYDIA SCREENING IN WOMEN AGES 16-24 (CHL)

Measure Steward: National Committee for Quality Assurance (NCQA)

Gold Coast Health Plan’s (GCHP) goal is to help its providers gain compliance with their annual Managed Care Accountability Set (MCAS) scores by providing guidance and resources. This tip sheet will provide the key components to the MCAS measure, “Chlamydia Screening in Women Ages 16-24 (CHL).”

Measure Description: The percentage of women ages 16-24 who were identified as sexually active and who had at least one test for chlamydia during the measurement year.

Data Collection Method: Administrative

Criteria to identify Eligible Population

- Evidence of sexual activity. Click here for a complete list of codes (ICD-10-CM, CPT, HCPCPS and SNOMED).
- Evidence of contraceptive prescription dispensing.

Contraceptive Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
</table>
| Contraceptives | Desogestrel-ethinyl estradiol  
   Dienogest-estradiol multiphasic  
   Drospirenon-ethinyl estradiol  
   Drospirenone-ethinyl estradiol-levomefolate biphasic  
   Ethinyl estradiol-ethynodiol  
   Ethinyl estradiol-etonogestrel  
   Ethinyl estradiol-folic acid-levonorgestrel  
   Ethinyl estradiol-levonorgestrel  
   Ethinyl estradiol-norelgestromin  
   Ethinyl estradiol-norethindrone  
   Ethinyl estradiol-norgestimate  
   Ethinyl estradiol-norgestrel  
   Etonogestrel  
   Levonorgestrel  
   Medroxyprogesterone  
   Mestranol-norethindrone  
   Norethindrone |
| Diaphragm | Diaphragm |
| Spermicide | Nonxynol 9 |
Codes used to identify chlamydia screening.

<table>
<thead>
<tr>
<th>Description</th>
<th>CPT</th>
<th>LOINC</th>
<th>SNOMED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlamydia Test</td>
<td>87110, 87270, 87320, 87490, 87491, 87492, 87810</td>
<td>14463-4, 14464-2, 14467-5, 14474-1, 14513-6, 16600-9, 21190-4, 21191-2, 21613-5, 23838-6, 31775-0, 31777-6, 36902-5, 36903-3, 42931-6, 43304-5, 43404-3, 43405-0, 43406-8, 44806-8, 44807-6, 45068-4, 45069-2, 45075-9, 45076-7, 45084-1, 45091-6, 45095-7, 45098-1, 45100-5, 47211-8, 47212-6, 49096-1, 4993-2, 50387-0, 53925-4, 53926-2, 557-9, 560-3, 6349-5, 6354-5, 6355-2, 6356-0, 6357-8, 80360-1, 80361-9, 80362-7, 91860-7</td>
<td>104175002, 104281002, 104282009, 104290009, 117775008, 121956002, 121957006, 121958001, 121959009, 122173003, 122540005, 122321005, 122322003, 134256004, 134289004, 171120003, 285586000, 310861008, 310862001, 315087006, 315094009, 315095005, 315099004, 390784004, 390785003, 395195000, 398452009, 399193003, 407707008, 442487003, 707982002</td>
</tr>
</tbody>
</table>

Best Practices:

- Include chlamydia screening as a part of routine clinical preventive care.
- Use normalizing and opt-out language, such as, “I recommend a test for chlamydia to all my clients under the age of 25.” AVOID questions like, “Do you want to be tested for chlamydia today?”
- Use the least invasive and highest quality recommended laboratory technologies available.
- Ensure your documentation is clear and concise.
- Use proper coding.

¹ Measures reported using the administrative data collection method report on the entire eligible population and use only administrative data sources (e.g., claims, encounter, lab, immunization registries) to evaluate if services were performed.